Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.

Martin Ridderstråle Julio RosenstockKnut R AndersenHans J WoerleAfshin Salsalinull null

Published in: Diabetes, obesity & metabolism (2018)

In patients with type 2 diabetes, empagliflozin 25 mg as add-on to metformin for 208 weeks reduced HbA1c with a significantly lower risk of hypoglycaemia and a significantly smaller proportion of patients receiving rescue therapy compared with glimepiride.

Keyphrases

randomized controlled trial
type diabetes
study protocol
electronic health record
big data
gestational age
systematic review
machine learning
newly diagnosed
data analysis
artificial intelligence
preterm birth
smoking cessation